Cryoport Raised 2026 Revenue Guidance-But EBITDA Is Still in the Red

Revenue guidance improved, but profitability still needs to follow

Cryoport's latest update gives investors a reason to pay attention without fully easing the risk. The company strengthened its 2026 revenue outlook, but it has not yet delivered consistent profitability.

The guidance raise looks grounded in demand

The main bullish point is simple: management raised full-year revenue guidance to $192 million-$196 million, after first-quarter revenue grew 16% year over year. That suggests management sees enough demand visibility to support a higher sales target, not just optimistic language.

The growth also looks broad-based rather than tied to one corner of the business. Life Sciences Products revenue rose 15%, Life Sciences Services revenue increased 18%, and commercial cell and gene therapy revenue grew 26%. That breadth makes the raise look more credible than a one-off spike.

EBITDA is closer to positive, but still negative

The key debate is whether higher revenue can finally move the company past losses. In Q1, Cryoport still posted adjusted EBITDA from continuing operations of negative $0.6 million. That is much closer to positive than the prior year, but it is still in the red.

So the picture is improving, but not yet clean. Bulls can point to better momentum and a more credible revenue base. Bears can argue that investors are still funding growth before operating leverage is fully proven.

Why the growth looks broader than a headline raise

The revenue increase matters less on its own than the operating activity underneath it.

Growth is showing up across multiple segments

In the first quarter, Life Sciences Products revenue rose 15% and Life Sciences Services revenue increased 18%. Commercial cell and gene therapy revenue also grew 26% to $9.1 million. That suggests demand is strengthening across products, services, and the commercial cell and gene therapy business at the same time.

When only one segment grows, investors have to wonder whether management got lucky. When several segments expand together, the guidance raise looks more like a reflection of real operating breadth.

More trials and approved therapies support the outlook

Cryoport said it was supporting a record 766 global clinical trials and 21 commercially approved CGTs as of March 31, 2026. That matters because more trials usually mean more sample and cold-chain activity, while more approved therapies can support more recurring commercial volume.

In other words, the business is being pulled by both the pipeline and the market. That helps explain why management lifted the full-year range instead of merely defending it.

Gross margin adds some confidence to the raise

Cryoport also reported gross margin of 45.8% in Q1. Gross margin is not a complete measure of profitability, but it does suggest the extra revenue is landing in a business with workable unit economics.

If revenue were growing mainly through low-value handling or heavy discounting, the quality of the guidance would be harder to trust. Here, the mix continues to lean toward services and specialized CGT support, where Cryoport can often build more stickiness.

The next test is whether EBITDA can turn positive

Demand no longer looks like the main unanswered question. The bigger question is whether that demand can break through the fixed-cost base and produce positive adjusted EBITDA.

The trend is improving, but the turn has not happened yet

Cryoport still posted adjusted EBITDA from continuing operations of negative $0.6 million in Q1, but that was an improvement tied to a $2.2 million improvement in adjusted EBITDA from a year earlier. The direction is right, but the company has not crossed into profitability yet.

For a specialized temperature-controlled supply-chain business, that is not surprising. Facilities, qualified storage, temperature-control systems, logistics coordination, and trained staff have to be in place before higher volume can fully absorb those costs.

Management has linked the EBITDA improvement to top-line growth combined with operational discipline and the use of generative AI to automate internal workflows. Growth is helping, cost control is helping, but not enough yet to eliminate the loss.

Why the second half matters

Management expects to achieve positive adjusted EBITDA in the second half of 2026, supported by organic revenue growth and the completion of key facility investments.

That expectation is practical rather than theoretical. If revenue keeps rising and the cost structure stops expanding at the same pace, each additional dollar of sales should contribute more to profit. The question is whether execution delivers that leverage in the second half.

What investors should watch next

The next signals matter more than the narrative: - Can adjusted EBITDA turn positive in the second half, or does the business remain a "less negative" story? - If it turns positive, will that positivity hold beyond a single quarter? - If new facility capacity matters more in 2027, what will show that the 2026 turn has real staying power?

For now, the setup is encouraging on revenue but still unresolved on profitability.